Non-Hodgkin’s lymphoma is the most common blood cancer worldwide. Mantel Cell Lymphoma (MCL) represents about 6 percent of all non-Hodgkin’s lymphoma. Despite advances in chemotherapy and immunotherapy, most Mante Cell Lymphoma (MCL) patients relapse and die of their disease. The Chemotherapy+ FOundation is supporting Dr. Parekh’s work on this stubborn killer. Dr. Parekh is studying the therapeutic development of moilecular inhibitors of a human protien that is encoded by the SOX11 gene. This gene is a highly specific marker for MCL and other hematological cancers.